



Our First Two Years

Review 2019-2021

A NEW TREATMENT PARADIGM IN MENTAL HEALTH

Level 1, 10 Dorcas Street
South Melbourne VIC 3205
Australia

CONTACT INFO

Phone: (03) 8679 6015
Email: hello@mindmedicineaustralia.org
www.mindmedicineaustralia.org

Contents

Fast Facts.....	3
A Message From Our Founders, Chair and Executive Director.....	4
Our Board.....	8
Our Vision.....	9
What is Psychedelic-Assisted Psychotherapy?.....	10
Our TGA Application.....	12
Our Events.....	14
Our Local Chapters.....	16
Our Volunteers.....	18
Psychological Support Services	19
Certificate in Psychedelic-Assisted Therapies (CPAT).....	21
Our People.....	23
With Thanks.....	25
Corporate Governance.....	26
Financial Report.....	27

"Some experts who are working in the field have told me the only way we'll ever get a cure for post-traumatic stress disorder is by the use of psychedelics."

– Admiral Chris Barrie AC

Fast Facts

“I felt like I went through 15 years of psychological therapy in one night.”


– Patient featured in Trip of Compassion

- Around the world psychedelic-assisted therapies are on the cusp of **widespread acceptance** as a breakthrough therapy for key classes of mental illness.
- These medicines have been shown to be **very safe and non-addictive when used in a medically controlled environment**.
- These therapies are being trialed as treatments for **depression, PTSD, anxiety, end-of-life distress, dementia, anorexia and eating disorders, opioid, alcohol and smoking addictions** and a number of other illnesses.
- These treatments are showing remission rates of **up to 80% after just 2-3 medicinal doses** in combination with psychotherapy.
- There have been over **160+ current or completed psychedelic trials** in the past decade.
- In the 50's/60's these medicines were considered the **next big breakthrough in treatments for mental illnesses** before the War on Drugs in 1970, which stopped further research for decades.
- Both psilocybin-assisted psychotherapy for major and treatment-resistant depression as well as MDMA-assisted psychotherapy for PTSD have been granted **“Breakthrough Therapy Designation” by the Food and Drug Administration (FDA)** in the USA to fast-track the approval process because clinical evidence to date indicates that they may demonstrate substantial improvement over currently available therapies.
- In the past 2 years **over 50 for-profit companies** have emerged in this space globally creating an **entire new industry, jobs and other opportunities for innovation in treatments**.

A Message From Our Founders, Chair and Executive Director

In our first two years we have made remarkable progress in growing public awareness of Psychedelic-Assisted Therapy in Australia. We are already seeing a paradigm shift in the curiosity, acceptance and interest into the use of psilocybin and MDMA assisted therapy for depression, addiction, PTSD, obsessive-compulsive disorder, anorexia and other mental and physical illnesses in our communities.

Our goal is to build the ecosystem for these treatments in Australia and ensure they are accessible to all who need them in medically controlled environments. Please see our key strategic objectives below.



What we have achieved in our two years with your support:

Awareness and Knowledge Building

- Successful sold-out launch event with Professor David Nutt at the University of Melbourne
- 130+ webinars, screenings and special events attracting 25,000+ participants
- 200+ regular donors
- 100+ media appearances

- 120,000+ visitors to our websites and over 51,800+ followers on our social media channels
- 3000+ downloads of our e-book about psychedelic-assisted psychotherapies
- 25,000+ people in our database incl. over 9000 health professionals and over 1000 psychiatrists
- 31+ local Chapters around Australia and New Zealand with 700+ members and growing
- 20+ world leading speakers for our International Summit on Psychedelic Therapies for Mental Illness to take place in Melbourne in November 2021
- 150+ partner organisations for our Summit so far
- Created a video animation explaining the mental health problem in Australia and the benefits of psilocybin and MDMA-assisted psychotherapy with over 50,000+ views
- Collating Australia's first book of Psychedelic Healing Stories
- Part-funder of St Vincent's end-of-life trial using psilocybin-assisted therapy

Access to Medically Approved Therapy

- Submission of our TGA application to reschedule MDMA and psilocybin from Schedule 9 (Prohibited Substances) to Schedule 8 (Controlled Medicines)
- Australia's TGA has granted approvals through SAS-B for psilocybin and MDMA assisted therapies for patients on a case-by-case basis
- Partnership announced between Emyria Limited (which owns a network of Emerald Clinics around Australia) and Mind Medicine Australia to develop a gold standard national care program, clinical protocols and standard operating practices for psychedelic-assisted therapies
- Submissions made to the Victorian Royal Commission on Mental Health and to the Productivity Commission
- Launch of our Psychological Support Service offering expert support in relation to psychedelics and plant medicines in terms of client emotional health and wellbeing
- Built national team of 11 practitioners including 1 psychotherapist, 5 psychologists, 1 GP, 1 nutritionist, 1 Trauma informed yoga teacher, 1 counsellor and 1 social worker
- 639+ sessions by all practitioners including 39 NDIS sessions
- 1249+ current patients and 759+ patients in our database
- 10,000+ medical practitioners in our database
- 130+ participants in our study and integration groups

- 10 social work student placements with over 5000 hours
- Key university partnerships with University of Melbourne, Victoria University, Deakin University and Australian Catholic University
- Contract signed with manufacturer of medical grade GMP standard psychedelic medicines for import to Australia when all necessary regulatory approvals have been obtained
- Review of Federal and State legislative and regulatory requirements

Professional Development Program (Certificate in Psychedelic-Assisted Therapies)

- Confirmed world-leading facilitators for our Certificate in Psychedelic-Assisted Therapies professional development course
- First intake commenced, fully subscribed and other intakes filling fast
- 100-200 therapists in training annually including GPs, psychiatrists, psychologists, psychotherapists, mental health nurses, social workers, occupational therapists, addiction specialists and counsellors.

Asia-Pacific Centre for Emerging Mental Health Therapies (CEMHT)

- Developing partnerships with Australian Universities to create an Asia-Pacific Centre of Excellence in Emerging Mental Health Therapies
- Discussions with key stakeholders continue

The progress we are making in public education was exemplified in several headline media articles including in the Australian Financial Review, The Australian, The Age, Herald Sun, The Saturday Paper and Vogue Australia and media interviews including with Channel Nine, Channel 10, The Project, ABC and numerous other TV and radio stations.

Our primary focus over the next couple of years will be on psilocybin-assisted psychotherapy and MDMA-assisted psychotherapy, given their **“Breakthrough Therapy Designation”** with the Food and Drug Administration (“FDA”) in the United States and the strong clinical evidence that supports both their effectiveness and safety. We are also interested in developing other medicines to treat a variety of conditions.

Behind the scenes, we are working closely with key stakeholders to ensure that **these therapies will be accessible and affordable to all Australians needing these treatments in medically-controlled environments**, so that cost and geography doesn't become a barrier.

In the last year, we have assembled a comprehensive **leadership team** with expertise in mental illness including psychology, neuroscience and pharmacology, non-profit development, business practices and networks,, public health, events and educational development.

Mind Medicine Australia is also supported by an outstanding **Board, Ambassadors and an Advisory Panel of over 60 local and international experts** in medicine, psychiatry, psychology, pharmacology, research, science more broadly, ethics, law, policy, anthropology, business and therapeutic practices.

We are currently preparing for our **International Summit on Psychedelic Therapies for Mental Illness** to be held at the Sofitel in Melbourne this November. We have a global line-up of world leaders in medicine-assisted psychotherapies and other outstanding thought leaders on topics ranging from medicine and anthropology to neuroscience and ethics. We are now confirming financial, endorsing and media partners and would appreciate as much support as possible to produce a brilliant event.

Our much anticipated **Certificate in Psychedelic-Assisted Therapies** commenced in January 2021 featuring a world class Faculty. We are thrilled to welcome a wonderful group of GPs, psychiatrists, psychologists, psychotherapists, mental health nurses, social workers, occupational therapists, addiction specialists and counsellors.

As we move through 2021, our vision and capacity continues to grow, as does the need to make these effective and safe therapies a legally available treatment through our medical system for the **increasing number of individuals suffering** as a result of the pandemic, environmental challenges and global trends which challenge social cohesiveness and social inclusion.

We ask for your continued and expanded support so that we can fund the path for psilocybin and MDMA assisted psychotherapy to help treat the millions experiencing key mental illnesses in Australia. This is personal for every one of us.

As psychiatrist Stan Grof said “...Psychedelics, used responsibly and with proper caution, would be for psychiatry what the microscope is for biology and medicine or the telescope is for astronomy.”

With gratitude for your interest and support



Peter Hunt AM

Chair



Tania de Jong AM

Executive Director

Our Board



Peter Hunt AM

CHAIR

Co-founder Mind Medicine Australia, Investment Banker & Engaged Philanthropist; Founder, Women's Community Shelters



Tania de Jong AM

DEPUTY CHAIR

Co-founder Mind Medicine Australia, Founder Creative Universe, Creativity Australia The Song Room & Creative Innovation Global



Admiral Chris Barrie AC

DIRECTOR

Chairman, Fearless - PTSD-Australia New Zealand; Former Chief of the Australian Defence Force



Professor Jane Burns

DIRECTOR

Chair of Open Arms, Chair of STREAT and Chair of the Centre for Mental Health, Swinburne University



Dr Eli Kotler

DIRECTOR

Medical Director at Malvern Private Hospital, Consultant Psychiatrist, Addiction and Trauma expert



Dr Simon Longstaff AO

DIRECTOR

Executive Director at the Ethics Centre



Monojit (Mono) Ray

DIRECTOR

CEO & Founder, ConnectAlex; Non-Executive Director, Kidney Health Australia



Hon Andrew Robb AO

DIRECTOR

Australia's Minister for Trade and Investment (2013-2016); Chair of Asia Link



Nicholas Smedley

DIRECTOR

Chairman, Respiro Limited

Our Vision



MIND MEDICINE
A U S T R A L I A

Mind Medicine Australia (MMA) is a charity that seeks to alleviate the suffering caused by mental illness in Australia through expanding the treatment options available to medical practitioners and their patients. We are focused on the development of safe and effective psychedelic-assisted therapies to cure a range of mental illnesses.

We are supporting clinical research and working towards regulatory-approved and evidence-based psychedelic-assisted therapies. We operate as a nexus between medical practitioners, academia, government, regulatory bodies, philanthropists, and other partners.

Mind Medicine Australia is focused specifically on the clinical application of medicinal psilocybin and medicinal MDMA for certain mental illnesses. We do not advocate for non-clinical use of psychedelics, MDMA, or any other prohibited substances, nor do we advocate for any changes to the law with respect to non-clinical use. Our focus is wholly clinical.




What is Psychedelic-Assisted Psychotherapy?

Psychedelic-assisted therapy typically involves ‘talk-therapy’ alongside the ingestion of a psychedelic such as psilocybin or MDMA. Researchers and clinicians often describe three distinct therapy phases:

- 1. Preparation**
- 2. The acute psychedelic experience**
- 3. Integration**

The non-psychedelic elements of this approach are essential for both effectiveness and safety.

These 3 phases are illustrated in the timeline below.




Various approaches to preparation have been developed, from diet to psychotherapy. In clinical trials, participants will typically attend a number of talk-therapy sessions with a trained therapist who will be in attendance during the psychedelic session. A therapeutic alliance is developed during this time, and the nature of the individual's struggle is explored.

During the psychedelic session, ‘set’ and ‘setting’ are considered paramount. ‘Set’ refers to mind-set, a complex mix of more transient phenomena like expectation and mood, and more enduring phenomena like personality and past experience. ‘Setting’ refers to the context or environment in which the session takes place, including basic factors like the comfort and aesthetic quality of the room, and more complex factors like the quality of the relationship with the clinicians and the mood they help to set. Whilst many modern clinical trials occur within hospitals or research institutes, the session rooms are made to appear as comfortable living rooms. There are typically two therapists in attendance. The patient can sit or lie on a couch, is often encouraged to wear eyeshades, and sometimes listen to a carefully-selected playlist of music. Oral ingestion of a capsule of synthesised psychedelic compound (e.g., psilocybin) is the most common route of administration, and the session will typically last for about 8 hours.

A common therapeutic approach during psychedelic sessions is to be non-directive: attentive but usually silent, supporting the emerging process, offering assistance and guidance if needed, listening and responding to the patient when they speak, with little analysis of the material. In some trials, a single high-dose psychedelic session occurs; in others, there are two or three high-dose sessions. Many trials are also placebo-controlled, wherein the patient will usually have one placebo session – sometimes a very low dose of the psychedelic, sometimes an ‘active placebo’ that produces some noticeable somatic effects – in addition to their high-dose session(s).

Immediately after the psychedelic session and in the following days, a process of integration is facilitated by the therapist. During these conversations, the patient has the opportunity to process, make sense of, and give meaningful expression to their psychedelic experience.

Psychedelic-assisted therapies have shown strong clinical results. Medicinal psilocybin and medicinal MDMA are very safe to use in a medically controlled environment and are non-addictive. Whilst MMA is focused on the medicinal use of psilocybin and MDMA, it should be noted that contrary to some assertions these are also amongst the safest recreational drugs.



Source: Nutt, D and Castle, D, et al. (2019) The Australian drug harms ranking study, Journal of Psychopharmacology, Vol 33, Issue 7

Our TGA Application

On February 3 2021, the TGA announced its Interim Decision not to amend the current Poisons Standard in relation to the use of medical grade psilocybin and medical grade MDMA as part of therapy to treat patients suffering from treatment resistant mental illnesses including Depression, PTSD and Substance Abuse. These therapies have been achieving outstanding remission rates in overseas trials, are being used in expanded access schemes in the United States, Canada, Switzerland and Israel and have been shown to be safe and non-addictive when used in medically controlled environments (e.g. hospitals and clinics).

The rescheduling applications were lodged last July and supported by over 80 leading psychiatrists, psychologists, pharmacologists, researchers and other medical practitioners. Whilst we are disappointed, we have to remember that these are only Interim Decisions. The enormous benefit that we now have is that the Delegate of the Secretary of the Department of Health has had to publish his reasons for making these Interim Decisions. We have lodged major submissions against the Interim Decisions and that has led to the TGA announcing an independent inquiry into rescheduling the medicines when used as part of therapy.

Our Progress

1

Wednesday 26th August 2020 – TGA publishes notices seeking submissions on the proposed rescheduling by Friday 25 September.

2

Monday 28th of September 2020 – The final date for making a submission closed at 5 pm (AEST). Following the submission of public comments, the submissions were reviewed by an expert committee.

3

Wednesday 3rd of February 2021 – Interim Decisions are published by the TGA against rescheduling.

4

Thursday 4th of March – MMA lodges major submissions against the interim decisions.

5

Wednesday 7th April 2021 – TGA announces an Independent Review.

Testimonials

"I have personally had three patients commit suicide in the past 5 months. All three patients were fully treated with the best available treatments including antidepressant therapy, psychotherapy, and intensive case management. It is frustrating and heart-breaking to have complete treatment failure in the majority of my patients with the best currently available therapies. I currently have another patient suffering end of life anxiety after a diagnosis of rapidly progressing motor neurone disease. She has requested psilocybin-assisted psychotherapy as she has tried every other available treatment without any relief of her symptoms. The evidence favouring the use of psilocybin to assist with end of life anxiety also appears very promising and there appear to be no side effects." – **Jessica Hickmott, Psychiatrist**

"Current first line therapies for post-traumatic stress disorder have limited efficacy, with pharmacological treatments usually requiring costly and potentially side-effect prone daily use. Only 5% of PTSD sufferers go into remission from existing treatments. Tragically, many of these patients are former soldiers and emergency responders who have spent their lives serving our nation" – **Jesse Schnall, Junior Medical Doctor**

"The most complex patients I see engage in regular therapy for years. For many, sub-optimal early life relationships and experiences have resulted in deeply ingrained belief systems which consider the patient to be unlovable, unworthy, and a source of shame. These "self-stories" are embedded within the Default Mode Network, a large-scale brain network which is highly active in rumination and self-criticism, and highly impervious to reason and re-framing. Traditional therapy can be beneficial, however the enormous commitment of time and finances required to begin to "re-story" these belief systems can be a challenge and is often an exclusory factor." – **Caroline Dale, Clinical Psychologist**



"Being born Jewish and having lost many of my relatives in the Holocaust, I've lived with inter-generational trauma for as long as I can remember. I was never really aware of what exactly was holding me back until I experienced supervised psilocybin treatments in the Netherlands. Since then I have been able to release and heal much of this trauma and also washed away lifetimes of collective trauma that we all carry along with us. I feel a deeper sense of identity, greater insight, compassion and connection. This has helped me to be more authentic and vulnerable in my relationships and has improved my productivity and creativity. It's like all these missing parts of myself have been found. I am more whole and much calmer." – **Tania de Jong AM, co-Founder of Mind Medicine Australia and lived experience**

"Mental health statistics in Australia and globally support the proposition that current treatments are woefully inadequate. There has been no effective innovation, no effective alternatives developed for many decades in regard to anti-depressants and PTSD. The pharmaceutical industry vacated the innovation space long ago." – **Andrew Robb, Chairman of the Robb Group**

Our Events

Mind Medicine Australia had a successful sold-out launch event with Professor David Nutt at the University of Melbourne in 2019. Since then we have produced over 130+ educational and Chapter events, which have included film screenings, Q&A panels and webinars with renowned international speakers. Our lineup of Australian and international speakers has included MAPS founder Dr Rick Doblin (USA), Psychiatrist Dr Stanislav Grof (Czech), Physician and Author Dr Gabor Maté (Canada), Psychiatrist Dr Ben Sessa (UK), Psychedelics Researcher Dr Robin Carhart-Harris (UK) and many more.

In addition to our own educational events, we have also taken part in 30+ education partnership events, such as the ACNEM and Psytech conferences.



International Summit



Mind Medicine Australia will hold a two-day International Summit on Psychedelic Therapies for Mental Illness in November 2021 in Melbourne, bringing together clinicians, scientists, academics, mental and public health professionals, philanthropists, investors, Government, law and policy leaders, business, industry, consumers and other interested stakeholders.

The event will also feature a **two-day pre-Summit introductory workshop program (17-18 November)** for anyone with an interest in the topic and who is considering further development of their current therapeutic skills or who are eager to gain a detailed understanding of **psychedelic-assisted psychotherapy for the treatment of mental illness**.

The Summit will feature a rich program with a mixture of international and national keynotes, workshops, hot spots, panel conversations and gala dinner with Q & A.

Leading international speakers confirmed for the 2-day summit and Mind Medicine Australia Ambassadors include: **Professor David Nutt (UK)** Head of Neuropsychopharmacology at Imperial College London and lead advisor on psilocybin assisted therapy for treatment-resistant depression, **Dr Rick Doblin (USA)** Founder and Executive Director, Multidisciplinary Association for Psychedelic Studies (MAPS), **Dr Gabor Maté (Canada)** renowned trauma and addiction physician, **Johann Hari (UK)** journalist and bestselling author, **Dr Ben Sessa (UK)** psychiatrist, researcher and writer and currently leading the Imperial College trials on using MDMA therapy for alcohol dependence, **Dr Robin Carhart-Harris (UK)** Head of the Centre for Psychedelic Research, Imperial College London, **Wade Davis CM (Canada)** Anthropologist, ethnobotanist and Explorer in Residence at the National Geographic Society, **Professor Matthew Johnson (USA)** Associate Professor of Psychiatry at Johns Hopkins University School of Medicine with a focus on psychedelic research for the treatment of mental illness, **Dr Adele Lafrance (USA)** Clinical Psychologist and Research Scientist, **Patrycja Slawuta (USA)** Researcher & Psychologist, **Dr Gabby Agin-Liebes (USA)** Psilocybin researcher and Weill Institute for Neuroscience, **Dr Kate Pate (USA)** Neurophysiologist and writer, **Dr Reid Robinson (USA)** Psychedelic Psychiatrist and writer, **Dr Adam Gazzaley (USA)** Founder & Executive Director – Neuroscape, **Shlomi Raz (USA)** Chairman and CEO of Eleusis, **John Skeritt (AUS)** Deputy Secretary, Health Products Regulation Group - TGA, **Dr Simon Longstaff (AUS)** Executive Director of The Ethics Centre, **Dr Eli Kotler (AUS)** Psychiatrist and Director of Medicine at Malvern Private Hospital... and more to be announced.

Our Local Chapters

2020 saw the beginning of Mind Medicine Australia's Chapters in all States across Australia, and recently, in major cities across New Zealand. Our Chapters are grassroots, community-led groups that operate in a way that is relevant, appropriate and considerate of the context of the local community that surrounds them. Our Chapters aim to build awareness, educate local health practitioners and politicians, cultivate understanding and to fundraise through events and other activities.

Amidst a year of bushfire recovery and COVID-19, the cracks of Australia's mental healthcare system became undeniably apparent. Australians in search of a new hope for mental healthcare joined our Chapters by the hundreds. From January 2020 to March 2021 we saw our total Chapter presence grow from under 50 members and 7 Chapters, to **over 700 members and 31 Chapters across Australia and New Zealand.**

The rapidly-changing and volatile landscape of 2020 meant that we had to rethink our timelines, activities and focus. The online space became an accessible and convenient platform for relationship building, foundation setting and leadership development. All of which have put our Chapters in a better position to achieve their goals in 2021.



Notwithstanding the difficulty of holding in-person activities in 2020, we were fortunate to be able to host four fantastic events with the support of our incredible Chapter members in Adelaide, Byron Bay, Cairns and the Gold Coast. These events brought together hundreds of people from the community and raised thousands of dollars in support of psychedelic medicine.

In 2021 we look forward to continuing to work with our members in Australia and New Zealand to support them in bringing the hope of psychedelic-assisted psychotherapy to those suffering in their local communities. We also look forward to establishing stronger relationships with student cohorts and supporting them to start their own related clubs at various universities.

We are incredibly grateful for the continued support of our members, partner venues and donors for supporting us to engage in meaningful collaboration with local communities and look forward to working together to make psychedelic-assisted therapy a reality in 2021.

31+ Chapters in Australia and New Zealand with 700+ Members



Australia:

- Adelaide
- Alice Springs
- Ballarat
- Blue Mountains
- Brisbane
- Byron Bay
- Cairns
- Canberra
- Castlemaine
- Coffs Harbour
- Dandenong Ranges
- Darwin
- Geelong
- Gold Coast
- Hobart
- Melbourne
- Newcastle
- Orange
- Perth
- Sydney
- Tamworth
- Wagga Wagga
- Wollongong

New Zealand:

- Auckland
- Christchurch
- Dunedin
- Wellington



Our Volunteers

Volunteers are the lifeblood of our organisation. As a not-for-profit organisation, we survive and thrive from the in-kind donations of our community. Although financial contributions are endlessly valuable for us, our volunteers contribute something greater.

In 2020, the support of our volunteers was critical in responding to the challenges Mind Medicine Australia faced throughout the COVID-19 crisis. With experts from every background and walk of life imaginable, we were able to draw upon knowledge and expertise to deliver a range of extremely high quality outcomes. From supporting the delivery of our enormous application to the TGA to reschedule psilocybin and MDMA, to providing expert insights and skillsets to create remarkable digital assets and strategies, to producing internationally commended policy research reports, to collating and transforming research into accessible-language blogs, assistance with partnerships, marketing, PR and social media. It is clear that we wouldn't be where we are today without the extraordinary contributions of our volunteers and we are continuously grateful and honoured to have their support.

In 2020, we have grown our non-chapter volunteer team to over 20 regular and sporadic volunteers from around Australia. We look forward to continue to work closely with our volunteer supporters in providing them with meaningful ways to interact with our organisation and to help make psychedelic-assisted psychotherapy a reality for our community in 2021.



"Volunteering with Mind Medicine Australia was a highly rewarding and meaningful experience. I was elated to collaborate with a diverse group of like-minded thinkers and expand on my research and communication skills. I would highly recommend volunteering with Mind Medicine Australia for anyone looking to learn more about this innovative and exciting field of work." - **Joud Ghassali**

"Mind Medicine Australia is a compassionate organisation made from compassionate individuals. Fostering each individual team member's growth has been a key ingredient to Mind Medicine Australia's success and accomplishments in the short time it has been operating." - **Daniel Renehan**



"My experience volunteering with Mind Medicine Australia was enriching both intellectually and professionally. I enjoyed working with a team of dedicated volunteers, including incredible professionals in the mental health space, as well as in communications and marketing. The experience has been invaluable to me and something that I highly recommend to anyone with a desire to improve the state of mental healthcare in Australia". - **Rachael Evans**

Psychological Support Services

Integrative health and wellbeing



Psychological Support Services is safe and professional psychological service for those who want support regarding psychedelics, plant medicines, and their emotional health and wellbeing. Our goal is to ensure that the Australian community has access to highly qualified and ethical allied and integrative health professionals so they can make safe and informed choices about their mental health in regard to psychedelics and plant medicines.

Dr Alana Roy is a Psychologist and Mental Health Social Worker. Her goal is to build an expert team of allied and integrative health practitioners around Australia drawing on CPAT candidates and professional networks to provide diagnosis, counselling, assessment, referral, psychoeducation, study and integration groups and short courses.

MMA Psychological Support Services employs Bachelor and Masters Social Work students from over 5 leading universities from around Australia on a range of advocacy, research and community development projects. The Social Work team seeks to break down the stigma of psychedelics in society and advocate for the mental health needs of disadvantaged and treatment resistant patients via community awareness and systemic change.

During 2021 our goal is to expand our allied health services team, service higher numbers of patients, develop short course content and promote on an international scale, expand university partnerships including 4+2 psychology internship programs.



Dr Alana Roy, Dr Jamie Rickcord, Ana Uribe Albornoz and Mark Baxter (from left).

639

Sessions by all
practitioners

39

NDIS
Sessions

1249

Patients

759

Patients in
our database

10k+

Medical Practitioners
in our database

9000+

Hours of social work
student placements



Key University
partnerships

¥ University of Melbourne

¥ Victoria University

¥ Deakin University

¥ Australian Catholic University

130

Participants in our study
and integration groups



MIND MEDICINE
AUSTRALIA


*"If the doors of perception were cleansed. Everything
would appear to man as it truly is... infinite."*

William Blake

Certificate in Psychedelic-Assisted Therapies (CPAT)

The course has been developed specifically with the objective of providing the clinical training necessary for existing qualified psychiatrists, psychologists, psychotherapists, GPs, physicians, mental health nurses, social workers, occupational therapists, drug and addiction specialists to work with patients utilising psilocybin and MDMA therapeutically in clinical environments.

In February 2021 we welcomed the first intake of students to our Melbourne event and workshop space for an Intensive Weekend Training as part of the course. It was a joy to see everyone coming together, learning and connecting with like-minded professionals.



Our People

AMBASSADORS

Dr Rick Doblin (USA)
Founder and Executive Director, Multidisciplinary Association for Psychedelic Studies (MAPS).

Professor David Nutt (UK)
Head of Neuropsychopharmacology at Imperial College London

Professor Roland Griffiths Ph.D
Professor of Psychiatry and Behavioural Sciences at Johns Hopkins School of Medicine

Dr Ben Sessa MD (UK)
Psychiatrist, Researcher & Writer

Dr Bill Richards (USA)
Psychologist in the Center for Psychedelic and Consciousness Research at the Johns Hopkins School of Medicine,

BOARD OF DIRECTORS

Peter Hunt AM
Co-founder Mind Medicine Australia, Investment Banker & Engaged Philanthropist; Founder, Women's Community Shelters

Tania de Jong AM
Co-founder Mind Medicine Australia, Founder, Creative Universe, Creativity Australia, The Song Room & Creative Innovation Global

Admiral Chris Barrie AC
Chairman, Fearless - PTSD-Australia New Zealand; Former Chief of the Australian Defence Force.

Professor Jane Burns
Chair of Open Arms, Chair of STREAT and Chair of the Centre for Mental Health, Swinburne University

Dr Eli Kotler
Medical Director at Malvern Private Hospital. Consultant Psychiatrist, Addiction and Trauma expert

Dr Simon Longstaff AO
Director, the Ethics Centre

Mono Ray
CEO & Founder, ConnectAlex; Non-Executive Director, Kidney Health Australia

The Hon Andrew Robb AO
Australia's Minister for Trade and Investment (2013-2016); Chair of Asia Link

Nicholas Smedley
Chairman, Respi Limited

ADVISORY PANEL

Scott T. Aaronson
Director of Clinical Research Programs and Adjunct Professor in the Department of Psychiatry

Dr Gabby Agin-Liebes (USA)
Clinical Psychologist

Dr Tanveer Ahmed
Psychiatrist and Author

Dr Mahsheed Ansari
Centre for Islamic Studies and Civilisation (CISAC) Charles Sturt University

Greg Barns
Barrister

Prof James Bennett-Levy
Professor of Mental Health and Psychological Wellbeing, University of Sydney

Prof Michael Berk
NHMRC Senior Principal Research Fellow

Prof Ashley Bush
NHMRC Senior Principal Research Fellow, Director of the Melbourne Dementia Research Centre

Dr David Caldicott
Adjunct Professor, University of Canberra & Emergency Consultant

Dr Robin Carhart-Harris (UK)
Founder, Centre for Psychedelic Research at Imperial College London

Dr Ted Cassidy
Psychiatrist and Co-Founder of TMS Australia

Dr Lynette Chazan
Psychiatrist, Psychoanalytic Psychotherapist & Teacher

Dr Mark Cross
Psychiatrist

Dr Wade Davis CM (Canada)
Anthropologist and writer

Dr James Fadiman (USA)
Psychologist and Author

Amanda Feilding (UK)
Founder and Executive Director of the Beckley Foundation

Prof Paul Fitzgerald
Professor of Psychiatry at Monash University and Director of the Epworth Centre for Innovation in Mental Health

Prof David Forbes
Psychologist

Prof Ian Freckelton
Queen's Counsel and Supreme Court Judge of Nauru

Prof Paul Frijters (UK)
Research Fellow London School of Economics

Prof Dr Karl J. Friston (UK)
Scientific Director: Wellcome Centre for Human Neuroimaging and Professor: Queen Square Institute of Neurology

Dr Albert Garcia-Romeu (USA)
A/Professor Johns Hopkins University School of Medicine

Dr Ingmar Gorman (USA)
Psychologist and Co-Founder of Fluence

Adam Grunsell AM CSC
Rear Admiral for the Australian Navy

Dr George Halasz
Consultant Child and Adolescent Psychiatrist and Adjunct Senior Lecturer, Monash University

David Heilpern
Barrister and Solicitor of the High Court of Australia and Author

Prof Gregg Henriques (USA)
Clinical Psychologist

Dr Karen Hitchcock
General Physician

Prof Malcolm Hopwood
Ramsay Health Care Professor of Psychiatry, University of Melbourne

Tommy Huppert
Founder and CEO of Cannatrek Limited

Prof Matthew W. Johnson (USA)
Associate Director at Johns Hopkins School of Medicine

Mark Joiner
Business Strategist and Finance Executive

Dr Linda Kader
Psychiatrist and Senior Lecturer at the Department of Psychiatry, University of Melbourne

Rabbi Zac Kamenetz
Educator, Rabbi and aspiring Healer

Rabbi Jeffrey Kamins OAM
Rabbinic Advisor and Founder at Voiceless

Michael Kornhauser
Pharmaceutical and Clinical Trial Research Specialist

Dr Adele Lafrance (USA)
Clinical Psychologist, Research Scientist and Author

Prof. Andrew Lawrence
NHMRC Principal Research Fellow & Division Head at the Florey Institute of Neuroscience & Mental Health

Scott Leckie
Human Rights Lawyer, Professor at Monash University and Found of Displacement Solutions

Rev Graham Long AM
Pastor Emeritus, The Wayside Chapel, Sydney

Dr Paul MacLeman
Corporate Advisor

Dr Gabor Maté CM (Canada)
Renowned speaker and bestselling author

Dennis McKenna (USA)
Ethnopharmacologist, Author, Founder Heffter Research Institute

Prof Rob Moodie AM
Professor of Public Health, University of Melbourne and Adviser to WHO

Dr David E. Nichols (USA)
Adjunct Professor of Chemical Biology and Medicinal Chemistry, University of North Carolina, Chapel Hill

Dr Nikola Ognyenovits
Addiction Medicine Specialist Physician

Dr Thomas Pogge (USA)
Philosopher & Director of the Global Justice Program at Yale

Nigel Pollard
Medicine Business Specialist

Dr Prash Puspanathan
Neuropsychiatry Fellow, Alfred Hospital, Melbourne

A/Prof Sathya Rao
Executive Clinical Director, Spectrum, Personality Disorder Service & Adjunct Clinical Associate Professor, Monash University

Dr Jamie Rickcord
Founder Ananda Clinics

Dr Reid Robison (USA)
Psychedelic Psychiatrist & Researcher

Dr Arne Rubinstein
Founder & CEO, The Rites of Passage Institute

Dr James Rucker (UK)
Consultant Psychiatrist & Senior Clinical Lecturer

Dr Stuart Saker
General Adult Psychiatrist with an interest in Veterans' Mental Health

Prof Avni Sali AM
Founding Director of NIIM, and Member of the Scientific Board of The European Congress for Integrative Medicine

Dr Patrycja Slawuta (USA)
Behavioural Scientist

Prof Margaret Somerville
Bioethicist

Imam Tawidi
Islamic Scholar, Educator, Author and Global
Speaker

Prof John Tiller
Professor Emeritus of Psychiatry, University of
Melbourne

Dr Jeremy Weate
CEO of Universal Ibogaine

Dr John Webber
Psychiatrist

Dr Michael Winkelman (USA)
Leader in neurotheological perspectives on
shamanism, traditional healing practices, and
altered states of consciousness

Dr Alex Wodak AM
Physician; Director of Australia 21 and President,
the Australian Drug Law Reform Foundation

Rabbi Dr Laibl Wolf
Dean and Founder of the Spiritgrow Wellness
Centre, Melbourne Australia

Dr Rachel Yehuda (USA)
Professor of Psychiatry and Neuroscience at the
Icahn School of Medicine at Mount Sinai

EXECUTIVE TEAM

Tania de Jong AM
Executive Director

Dr Alana Roy
Practice Manager

Ilan Hayman
Operations Manager

Scarlet Barnett
Events, Chapters, Partnerships and
Communications Manager

Diego Pinzon
Chapters, Engagement and Research Officer


Julia Neubauer
Digital Communications, Design and Social Media
Consultant

Melissa Warner
Education and Communications Fellow

Kimberley Day
Administration, Events, Partnerships and
Research Coordinator

Jeffrey Lee
Financial and Operations Officer

Victor Chiruta
Science Scholar



**"One week of intensive treatment
provided transformational healing."**
- Joel Harrop, Veterans of War, ex-ADF Veteran

With Thanks

Major individual supporters

Rebecca Adams
David Barlow
Mark Baxter
Hugo Bunk
Brendan Byrne
Paul Cave
Imm Chew
Elaine Connor
Xavier Desdoigts
David Frid
Stephen Grant
Matt Hutton
Mark Joiner
Henri de Jong
Stephen Lawes
Jeremy Leitch
Hannah Marsden
Michael Norster
Charlotte Peterswald
William Richardson
G G Aviation Pty Limited (Tony Shields)
Nicholas Smedley
David Taylor
Sandra Tracy
Kirk Veitch
Ian Ward-Ambler
Ray Wilson and Plenary Group

Ian & Linda Martin Charitable Foundation
Kerridge Foundation
Kestin Family Foundation
Kikoi
Mark Joiner
Orgill Foundation
Sofia Foundation Pty Ltd ATF
The L & R Uechtritz Foundation
The Saturday Paper Pty Ltd
Vasudara Foundation

In-kind supporters

APOC
Bekl and Eva Liu
Bloom Journals
Byron Theatre
Creative Universe
Creative Innovation Global
Cromitol®
Dimension5
Elektra Magnesium
Highbration
Murchisons
Sofitel Melbourne On Collins

Trust and foundation supporters

APS Foundation - Freeland Family Gift Fund
APS Foundation -Susanne Dahn
G G Aviation Pty Limited (Tony Shields)
Hunt Family Foundation
IIG Catalyst Fund

Corporate Governance

Meetings of directors

During the period covered by this Review, there were 6 Board Meetings of Directors. Attendances by each Director during the period were as follows:

Board Member	Number eligible to attend	Number attended
Peter Hunt AM	6	6
Tania de Jong AM	6	6
Admiral Chris Barrie AC	6	4
Professor Jane Burns	6	4
Dr Eli Kotler***	1	1
Dr Simon Longstaff AO	6	4
Monojit (Mono) Ray	6	6
Hon Andrew Robb AO	4	4
Nicholas Smedley	4	4
Professor David Castle*	4	4
Luke Mitchell**	2	2

*Professor David Castle resigned in 2020

**Luke Mitchell resigned in 2020

***Dr Eli Kotler joined in September 2020

Company particulars

Mind Medicine Australia Limited

ABN: 62 630 150 873

Level 1, 10 Dorcas Street

South Melbourne VIC 3205

Mind Medicine Australia Limited is a company limited by guarantee, incorporated in Australia and having its principal place of business at the address listed above.

The charity has deductible gift recipient (DGR) status; all donations are tax-deductible.

Financial Report

Mind Medicine Australia

ABN 62 630 150 873

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE YEAR ENDED 30 JUNE 2020

	Note	2020 \$	2019 \$
Conference Income		72,459	-
Donations - Events		39,918	-
Donations - Individuals		65,040	68,229
Donations - Trusts and Foundations		401,207	122,500
Other Income		48,120	-
Gross Profit		626,744	190,729
Interest Income		46	152
		626,790	190,881
Consulting and Professional fees		(136,395)	(32,083)
Donations		(54,647)	-
Employee benefits		(220,368)	(56,777)
Other expenses		(144,712)	(50,697)
Rent		(24,314)	-
Finance costs		(3,168)	(783)
Total Expenses		(583,604)	(140,340)
Profit before income tax		43,186	50,541
Income tax expense		-	-
Net Profit		43,186	50,541
Other comprehensive income:			-
Total comprehensive income for the year		43,186	50,541

Mind Medicine Australia
ABN 62 630 150 873
STATEMENT OF FINANCIAL POSITION AS AT 30 JUNE 2020

	Note	2020	2019
		\$	\$
ASSETS			
CURRENT ASSETS			
Cash and cash equivalents	4	294,830	53,999
Accounts Receivable	5	3,795	-
TOTAL CURRENT ASSETS		298,625	53,999
NON-CURRENT ASSETS			
Other assets	6	7,578	9,738
TOTAL NON-CURRENT ASSETS		7,578	9,738
TOTAL ASSETS		306,203	63,737
LIABILITIES			
CURRENT LIABILITIES			
Trade and other payables	7	56,924	13,196
Employee provisions	8	6,930	-
Deposits	9	148,622	-
TOTAL CURRENT LIABILITIES		212,476	13,196
TOTAL LIABILITIES		212,476	13,196
NET ASSETS		93,727	50,541
EQUITY			
Retained earnings	10	93,727	50,541
TOTAL EQUITY		93,727	50,541

Mind Medicine Australia
ABN 62 630 150 873

STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 30 JUNE 2020

	Retained Earnings	Total
	\$	\$
Balance at 1 July 2018	-	-
Comprehensive income		
Profit for the year	50,541	50,541
Other comprehensive income for the year	-	-
Total comprehensive income	50,541	50,541
Balance at 30 June 2019	50,541	50,541
Comprehensive income		
Profit for the year	43,186	43,186
Other comprehensive income for the year	-	-
Total comprehensive income	43,186	43,186
Balance at 30 June 2020	93,727	93,727

Mind Medicine Australia
ABN 62 630 150 873
STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 30 JUNE 2020

	Note	2020 \$	2019 \$
CASH FLOWS FROM OPERATING ACTIVITIES			
Receipts from customers		116,785	-
Payments to suppliers and employees		(532,201)	(136,882)
Interest received		46	152
Donations received		654,787	190,729
Net cash provided by operating activities	12	239,417	53,999
CASH FLOWS FROM FINANCING ACTIVITIES			
Net proceeds from / (repayment of) borrowings		1,414	-
Net cash provided by / (used in) financing activities		1,414	-
Net (decrease)/increase in cash and cash equivalents held		240,831	53,999
Cash at beginning of the financial year		53,999	-
Cash at end of the financial year	4	294,830	53,999

“...everyone deserved to have this experience... that if everyone did, no one could ever do harm to another again ... wars would be impossible to wage.”
 – New York University end-of-life study participant

"I have had severe PTSD for 34 years since the age of 19, following a childhood of physical, emotional and sexual abuse. Over that period I had been treated by 18 therapists, including 3 psychiatrists, and had been hospitalised following a failed suicide attempt. 3 years ago I moved to Amsterdam where I was able to receive MDMA-assisted therapy for PTSD following the MAPS protocol. I had 3 such sessions and experienced a complete cessation of all PTSD symptoms. The psychedelic experiences themselves were the most profound healing experiences of my life and relieved me of the burden of pain, terror and shame I had been carrying. I am now re-assessing my life from a 'post-PTSD' perspective, something I never thought I would see. It has been like giving me a new life."

- Steve Ball



*"Hold your shadow in front of you.
It can only take you down from behind." - Carl Jung*

Mind Medicine Australia
Level 1, 10 Dorcas Street
South Melbourne VIC 3205, Australia
Phone: (03) 8679 6015
hello@mindmedicineaustralia.org
www.mindmedicineaustralia.org